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METHODS: 1) Establishing the curriculum: The topics
of lectures which are important and of concern to the
general population were formulated through the survey
of pharmacists, pharmacy school faculty, and representa-
tives from consumer groups; 2) Developing teaching
material: After recognizing the topics, several groups of
pharmacists and pharmacy school faculty started writing
up the content of lectures; 3) Recruiting and training the
lecturers: Regional hospitals and pharmacist associations
were invited to recommend pharmacists for lecturers with
certain requisites. Then, four training sections were held
in four geographic regions in Taiwan; and 4) Coordina-
tion of the course program: Twenty community uni-
versities were participated in this project through the
coordination of the National Association for the Promo-
tion of Community Universities. RESULTS: Eighteen 
lectures (14 topics and 4 special lectures) were suggested
by the committee. Two sets of teaching material for 
lecturers and participants, respectively, were developed.
Four 16-hour training sections were completed in the
early December of 2002. One hundred ﬁfty selected out
of 190 pharmacists were ofﬁcially granted as the lectur-
ers. CONCLUSION: The curriculum will be implemented
in March 2003 in 20 community universities wide-spread
around the area of Taiwan.
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OBJECTIVES: Medicaid, and thus states, pay for the
majority of long term care delivered in the U.S. Nursing
homes discard large amounts of prescription drugs; esti-
mates are as high as 30% of the prescribed drugs in these
sites are discarded. The purpose of this preliminary study
is to analyze the dynamics of discarded drugs in nursing
homes. This is an important area of interest to policy-
makers and state ofﬁcials due to continuing budget 
constraints and increasing nursing home patient needs.
METHODS: This retrospective study reviews and 
analyzes prescription drug discard records and resident
demographic information for an entire year on two
nursing homes in a Southeastern state. One nursing home
is small, 50 beds, and the other is large, 213 beds. Simple
frequencies and cross-tabulations were run on the vari-
ables. RESULTS: There was an annual average of 12 dis-
carded drugs per nursing home bed with up to 69 drugs
discarded annually on individual nursing home residents.
Only about 5% of the discarded drugs were expired, with
the remaining discarded due to medicine discontinued on
that resident, or because the resident was discharged or
died. Approximately 25% of all drugs discarded during
the year of study were during the ﬁrst 6 months of the
resident being admitted to the nursing home, and 38% of
those were due to medication discontinuation. Signiﬁcant
differences exist in several variables, such as resident age
and medication type and reason for the medication being
discarded, between the two facilities. CONCLUSIONS:
This study categorizes the discarded drugs and shows 
the variety of drugs used in nursing homes. Formularies,
smaller initial dosages, and automated drug dispensers
are some possible solutions to help control the overall
increasing costs incurred, and, more speciﬁcally, to
control the large number of perfectly good prescription
drugs from being discarded.
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OBJECTIVE: The role of the state in providing health-
care is continually debated. In most developed economies,
public subsidy of pharmaceuticals distorts the market 
and has efﬁciency and equity considerations for govern-
ment, community and the pharmaceutical industry. 
This presentation discusses the economic case for and
against public intervention, and examines its impact.
METHODS: The argument for public subsidy states that
standard market mechanisms applied to pharmaceutical
markets do not necessarily produce the most efﬁcient or
equitable outcomes available. This is due to market 
failures associated with the use of prescription medicines.
Also, patients may undervalue social and personal health
beneﬁts obtained from medicines and may therefore
underconsume. Not all patients who are willing to pay
for medicines at the socially optimal price are able to 
do so. Publicly funded systems act to reduce prices by
altering the market dynamics. It is only when patients
overvalue beneﬁts of drugs that public subsidy leads to
overuse of prescription medicines. RESULTS: These
issues of market failure are addressed. It has been 
estimated that the Pharmaceutical Beneﬁts Scheme
subsidy contributes approximately $200 million annually
in improved efﬁciency to the Australian economy. It also
achieves equity improvements, as the highest PBS 
subsidies are received by lower income earners and the
aged. CONCLUSIONS: The pharmaceutical market in
Australia is relatively small in global terms. When gov-
ernment monopsony power is imposed on larger markets,
the potential decreased returns to pharmaceutical pro-
ducers may impact negatively on the incentives and ability
to innovate, placing future development of new medicines
at risk.
